<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00273728</url>
  </required_header>
  <id_info>
    <org_study_id>Swissmedic: 2005DR3123</org_study_id>
    <secondary_id>EKBB: EK 244/04</secondary_id>
    <nct_id>NCT00273728</nct_id>
  </id_info>
  <brief_title>BaSES Trial: Basel Starch Evaluation in Sepsis</brief_title>
  <acronym>BaSES</acronym>
  <official_title>Basel Study for Evaluation of Starch (130;0.4) Infusion in Septic Patients: BaSES (130;0.4) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fresenius AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: In patients with severe sepsis and septic shock early aggressive volume
      replacement reduced mortality. Standard infusion therapy consists of crystalloid infusions.
      The role of modern, low molecular weight, starch preparations and their influence on the
      course of disease is not determined yet.

      Hypothesis: The purpose of this study is to determine wether initial infusion therapy with
      Hydroxyethylstarch and Ringer's lactate reduces in septic patients reduces Intensive Care
      Unit and hospital length of stay without impairment of renal function

      Design: Double-blind, randomized, controlled monocentric study

      Setting: Intensive Care Units of a University Hospital

      Patients: 240 consecutive patients with sepsis, severe sepsis and septic shock

      Intervention: Volume therapy with Ringer's lactate and saline or hydroxy-ethyl starch (MW
      130, substitution 0.4) in the first five days of intensive care treatment.

      Parameter:

        -  Intensive Care length of stay

        -  Hospital length of stay

        -  Mortality

        -  Kidney function

      Statistics: Mann-Whitney test for non-parametric data like intensive care length of stay.
      Unpaired t-Test for kidney function parameters.

      Study withdrawal: Significant impairment of kidney function parameters in the hydroxy-ethyl
      starch group
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intensive Care length of stay</measure>
    <time_frame>time to discharge from the Intensive care unit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>time to discharge from the hospital</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>intesive care, hospital and one year mortality</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kidney function</measure>
    <time_frame>at intensive care discharge and after one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung function</measure>
    <time_frame>during intensive care</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">231</enrollment>
  <condition>Sepsis</condition>
  <condition>Severe Sepsis</condition>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>HES, Septic shock, resuscitation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>study group with HES 6%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydroxy-ethyl starch (MW 130; 0.4) vs. normal saline</intervention_name>
    <description>hydroxy-ethyl starch together with ringer's lactate versus physiologic saline together with saline</description>
    <arm_group_label>HES, Septic shock, resuscitation</arm_group_label>
    <other_name>Voluven</other_name>
    <other_name>Ringer's lactate</other_name>
    <other_name>NaCl 0.9%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with suspected or proven infection and 2 of the following 6 criteria:

          -  Body temperature &lt;36 or &gt;38.3Â° celsius

          -  Heart rate &gt; 90 beats/min

          -  Tachypnea &gt; 20/min or a arterial pCO2 below 4.25 kPa

          -  White blood cell count higher than 12.000 or below 4.000 or more than 10% immature
             forms

          -  Systolic blood pressure &lt;90 mmHg or mean arterial pressure &lt; 65 mmHg

          -  Altered mental state or oliguria

        Exclusion Criteria:

          -  Pregnancy

          -  Age below 18

          -  Allergy against Hydroxyethyl starch

          -  Chronic renal insufficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Siegemund, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anaesthesia and Intensive Care, State Hospital, CH-5404 Baden, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Surgical ICU, University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical ICU, Univesity Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.medana.unibas.ch/</url>
    <description>Link to the homepage of the Department of Anaesthesia and Intensive Care Basel, Switzerland</description>
  </link>
  <reference>
    <citation>Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M; Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001 Nov 8;345(19):1368-77.</citation>
    <PMID>11794169</PMID>
  </reference>
  <reference>
    <citation>Vincent JL, Gerlach H. Fluid resuscitation in severe sepsis and septic shock: an evidence-based review. Crit Care Med. 2004 Nov;32(11 Suppl):S451-4. Review.</citation>
    <PMID>15542955</PMID>
  </reference>
  <reference>
    <citation>Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R; SAFE Study Investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004 May 27;350(22):2247-56.</citation>
    <PMID>15163774</PMID>
  </reference>
  <reference>
    <citation>Schortgen F, Lacherade JC, Bruneel F, Cattaneo I, Hemery F, Lemaire F, Brochard L. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet. 2001 Mar 24;357(9260):911-6.</citation>
    <PMID>11289347</PMID>
  </reference>
  <reference>
    <citation>De Backer D, Creteur J, Preiser JC, Dubois MJ, Vincent JL. Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit Care Med. 2002 Jul 1;166(1):98-104.</citation>
    <PMID>12091178</PMID>
  </reference>
  <reference>
    <citation>Dellinger RP. Cardiovascular management of septic shock. Crit Care Med. 2003 Mar;31(3):946-55. Review.</citation>
    <PMID>12627010</PMID>
  </reference>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2006</study_first_submitted>
  <study_first_submitted_qc>January 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2006</study_first_posted>
  <last_update_submitted>August 11, 2011</last_update_submitted>
  <last_update_submitted_qc>August 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2011</last_update_posted>
  <responsible_party>
    <name_title>PD Dr M. Siegemund</name_title>
    <organization>University Hospital Basel</organization>
  </responsible_party>
  <keyword>Hydroxyethyl Starch</keyword>
  <keyword>shock, septic</keyword>
  <keyword>infusion, intravenous</keyword>
  <keyword>mortality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

